glp 1 agonist dpp 4 inhibitor GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? GLP-1 Receptor Agonists Have better

But science is reshaping the field

For adults with type 2 diabetes and established atherosclerotic cardiovascular disease, high cardiovascular risk, chronic kidney disease, or heart failure, guidelines recommend GLP-1 agonists with proven cardiovascular benefit as preferred agents, independent of metformin use or baseline A1C

In addition, a recent in silico molecular docking study regarding the DPP4/CTNNB1/MET signatures showed that stagliptin could be a potential TC drug, however more investigations are surely needed to confirm it ( Gemigliptin Gemigliptin is an orally bioavailable inhibitor of DPP-4, with hypoglycemic and potential renoprotective activities

Some fans even begin their research by skimming community forums or quick-search trends

SURMOUNT-4 will address the question of weight regain after stopping the drug: patients who took tirzepatide for 6 months, will be assessed for sustained weight loss one year later (NCT04660643)